Today's Trend
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) has recently traded higher, with investor sentiment likely supported by HC Wainwright’s continued Buy rating and $10 price target. However, the research update also included broad reductions to future earnings estimates, creating a mixed outlook.
- HC Wainwright maintained its Buy rating and $10 price target, implying substantial upside from recent trading levels. The firm continues to project improving results over time, with losses narrowing to $0.18 per share by fiscal 2030. Zentalis Pharmaceuticals stock analysis
- Reported short-interest data showed zero shares short on both July 27 and August 11, with a 0.0-day days-to-cover ratio. Because the figures produced an invalid percentage change and appear inconsistent with a meaningful short-interest report, they provide no reliable trading signal.
- HC Wainwright lowered its 2026 EPS forecast to a loss of $2.39 from $2.19 and reduced its Q3 and Q4 2026 forecasts to losses of $0.63 and $0.66 per share, respectively. The downward revisions point to higher expected expenses or slower progress toward profitability.
- The analyst also cut longer-term forecasts: FY2027 EPS to a $2.76 loss from $2.32, FY2028 to a $2.13 loss from $1.80, FY2029 to a $1.00 loss from $0.77, and FY2030 to a $0.18 loss from $0.01. These revisions suggest profitability may arrive later and be weaker than previously expected.
Overall, the stock’s increase appears to reflect the bullish rating and $10 valuation target, while the extensive EPS reductions highlight significant execution, funding, and clinical-development risks. Zentalis remains loss-making, and its latest quarterly EPS also missed consensus estimates.